Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis

Xuewei Ye a, Komal Anjum a, Tengfei Song a, Wenling Wang a, Ying Liang a, Mengxuan Chen a, Haocai Huang a, Xiao-Yuan Lian b, Zhizhen Zhang a, b

a Ocean College, Zhoushan Campus, Zhejiang University, Zhoushan 316021, China
b College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

ABSTRACT

Two cyclodepsipeptides and a known cyclodepsipeptide valinomycin were isolated from a culture of the marine actinomycete Streptomyces sp. P11-23B. Their structures were established based on NMR, HRESIMS, and MS-MS spectroscopic interpretation as well as by chemical degradation. Both streptodepsipeptides P11A and P11B inhibited proliferation of different glioma cell lines, with IC50 values ranging from 0.1 µM to 1.4 µM. Streptodepsipeptide P11A was found to block the cell cycle at the G0/G1 phase and induce apoptosis in glioma cells. Further investigation demonstrated that streptodepsipeptide P11A downregulated expression of HK2, PFKFB3, PKM2, GLS, and FASN, important tumor metabolic enzymes. Data from this study suggested that targeting multiple tumor metabolic regulators might be one anti-glioma mechanism of streptodepsipeptide P11A. A possible mechanism for this class of streptodepsipeptides is reported herein.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Gliomas are the most common and high death malignant brain tumors (Patil et al., 2013; Ru et al., 2013) and can be located at many important brain function areas, which make surgical resection extremely difficult. Therefore, chemotherapy has played a more important role in treatment and prevention of gliomas. However, so far very few drugs have been approved for treating gliomas including temozolomide (TMZ), carmustine, and lomustine. Of these, only TMZ has been independently used for treatment of gliomas. Furthermore, most current anti-glioma drugs are cytotoxicity-based alkylating agents with limited efficacy and serious side-effects (Chamberlain, 2010; Mittal et al., 2015). Therefore, there is an urgent need to discover lead compounds for development of novel anti-glioma drugs. Marine-derived natural products are important sources for discovery of new anticancer drug leads (Newman and Cragg, 2014; Petit and Biard, 2013; Schumacher et al., 2011).

Enhanced glycolysis, elevated glutaminolysis, and exacerbated lipogenesis, which are required for the rapid and unlimited proliferation of tumor cells, have been demonstrated as prominent hallmarks in glioma metabolism (Galluzzi et al., 2013; Guo et al., 2013; Vander Heiden, 2011; Ru et al., 2013). There are several important regulators (enzymes) in the glycolytic pathway, such as hexokinase 2 (HK2) (Vander Heiden, 2011; Wolf et al., 2011), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) (Kessler et al., 2008; Vander Heiden, 2011), and pyruvate kinase M2 (PKM2) (Kefas et al., 2010; Vander Heiden, 2011), that have been shown to be up-regulated in the glioma cells. These specific regulators are preferentially used by cancer cells (Vander Heiden, 2011). Glutamine metabolism (Daye and Wellen, 2012; Ru et al., 2013) and lipid metabolism (Guo et al., 2013; Ru et al., 2013; Santos and Schulze, 2012) have also been found to be largely altered in cancer cells. Both glutaminase (GLS, a key enzyme of glutaminolysis) (Daye and Wellen, 2012; Lu et al., 2010; Ru et al., 2013) and fatty acid synthase (FASN, a key lipogenic enzyme) (Menendez and Lupu, 2007; Ru et al., 2013) are up-regulated in gliomas. Accumulated
studies have demonstrated that the above mentioned metabolic enzymes are promising targets for discovery of novel anticancer drugs.

As part of an ongoing project for discovery of novel anti-glioma and antibacterial compounds from marine resources (Chen et al., 2015; Liang et al., 2016; Xin et al., 2012; Yu et al., 2014, 2015), a crude extract prepared from the culture of marine bacterium strain P11-23B was found to significantly inhibit proliferation of human glioma cells. Chemical investigation of this active extract led to the isolation of two new cyclodepsipeptides, which were named as glioma cells. Chemical investigation of this active extract led to a 1361 bp stretch of sequence (Supplementary Data, Figure S1 and Table S1). Those of seven 16S rDNA gene sequence, which matched (99% identity for a 2015; Liang et al., 2016; Xin et al., 2012; Yu et al., 2014, 2015), a well known to enhance the $K_\text{þ}$ permeability of several membrane systems including mitochondria, erythrocytes, and lipid bilayers (Heisey et al., 1988; Lim et al., 2007; Park et al., 2008; Pettit et al., 1999) and six ester groups. Acid hydrolysis of the new compounds, and their bioactivity against glioma cells and effect on the tumor metabolic regulators.

2. Results and discussion

Strain P11-23B was isolated from a marine mud sample and assigned as Streptomyces sp. P11-23B based on the analysis of its 16S rDNA gene sequence, which matched (99% identity for a 1361 bp stretch of sequence) those of seven Streptomyces strains (Supplementary Data, Figure S1 and Table S1). Culture of this marine actinomycete was grown in Gause’s liquid medium (50.0 L). The extract prepared from the culture of P11-23B showed significant activity against the proliferation of human glioma cells with inhibitions of 87.17% for glioma U87-MG cells and 86.84% for U251 cells. Separation of this active extract by ODS column chromatography, following by HPLC purification, afforded three compounds 1–3.

Compound 1 was proved to be the known cyclodepsipeptide valinomycin based on its NMR and HRESIMS data, melting point, optical rotation value, the analysis of its acidic hydrolysates by chiral HPLC and GC analyses, and the comparison with literature data (Pettit et al., 1999; Tabeta and Saito, 1985). Valinomycin (1) was previously isolated from several Streptomyces species (Heisey et al., 1988; Lim et al., 2007; Park et al., 2008; Pettit et al., 1999) and is well known to enhance the $K_\text{þ}$ permeability of several membrane systems including mitochondria, erythrocytes, and lipid bilayers (Bhattacharyya et al., 1971; Haynes et al., 1969). This cyclodepsipeptide was also reported to have activities against tumors, bacteria, fungi (Lim et al., 2007; Park et al., 2008; Pettit et al., 1999), and severe acute respiratory-syndrome coronavirus (Wu et al., 2004). Valinomycin (1) is composed of four units of D-valine (D-Val), L-valine (L-Val), D-α-hydroxyisovaleric acid (D-Hiv), and L-lactate (L-Lac) with a trimer structure of cyclo-(D-Val-L-Lac-L-Val-D-Hiv)$_3$. For its $^{13}$C and $^1$H NMR spectroscopic data assignments, see Table S2 (Supplementary Data). It was noted that each of the four units displayed characteristic NMR signals, which allowed for differentiation of the four units. The unit L-Lac was easily recognized by its NMR signals of δC 172.7 (C-1), 70.4 (C-2), 17.3 (C-3) and δH 5.32 (1H, q, J = 7.0 Hz, H-2) and 1.44 (3H, d, J = 7.0 Hz, H-3), while D-Hiv had its characteristic signals of δC 171.0 (C-1), 78.7 (C-2), 30.4 (C-3), 16.8 (C-4) and δH 5.02 (1H, d, J = 3.11 Hz, H-2). The D-Val and L-Val could be distinguished from their chemical shifts of C-1, C-2, H-2 and the coupling constant values of $^3$JCH-NH. The unit D-Val was indicated by its characteristic NMR signals at δC 170.2 (C-1), 59.1 (C-2) and δH 4.10 (1H, dd, J = 10.0, 8.1 Hz, H-2), 7.88 (1H, d, J = 8.1 Hz, NH-2), as compared with their counterparts of L-Val at δC 172.0 (C-1), 60.6 (C-2) and δH 3.96 (1H, dd, J = 10.2, 6.2 Hz, H-2), 7.80 (1H, d, J = 6.2 Hz, NH-2). All of these characteristic NMR signals mentioned above are very helpful for the structure elucidation of the new compounds of streptodepsipeptides P11A (2) and P11B (3), which had very complicated NMR signals.

The HRESIMS spectrum of compound 2 displayed ions at m/z 1095.6051 ([M–H]$^-$) and 1097.6227 ([M+H]$^+$), corresponding to the molecular formula of C$_{53}$H$_{88}$N$_6$O$_{18}$. Its $^{13}$C NMR spectrum showed 53 carbon resonances, which were distributed in six zones. The first zone displayed 12 carbonyl carbon (C-1) signals at δC 170.28–172.80. Six carbon signals at δC 70.41–78.93 in the second zone were assigned to six oxymethines (α–CH–O) and six resonances at δC 58.98–60.75 in the third zone were contributed to six nitrogenated methines (α–CH–N). The fourth zone exhibited eight methines (β–CH) at δC 28.49–30.41 and one carbon signal at δC 25.16 in the fifth zone was assigned to a methylene (β–CH$_2$). The remaining 20 carbons, which appeared at δC 9.41–19.92 in the sixth zone, were assigned to 20 methyls (γ–CH$_3$ or β–CH$_3$). The $^1$H NMR spectrum of 2 also showed six NH signals at δH 7.89 (d, 7.9 Hz), 7.84 (d, 6.0 Hz), 7.83 (d, 8.0 Hz), 7.83 (d, 8.0 Hz), 7.77 (d, 6.2 Hz), and 7.76 (d, 5.8 Hz). All of the above data suggested that compound 2 was composed of 12 units, including six amide groups (amino acids) and six ester groups. Acid hydrolysis of 2 produced D-Val, L-Val, D-Hiv, L-Lac, D-2-hydroxybutanoic acid (D-Hba) as determined by chiral HPLC and GC analyses using the standard compounds as references. Detailed COSY, HSQC, and HMBC spectroscopic analyses confirmed the presence of 12 units including three L-lactates, three L-valines, three D-valines, two D-α-hydroxyisovaleric acids, and one D-2-hydroxybutanoic acid (D-Hba). As shown in Fig. 2, the α-NH and α–CH protons of each valine had a COSY correlation, while the α–CH proton of each unit displayed a COSY correlation with the β–CH (or β–CH$_2$ for D-Hba, or β–CH$_2$ for L-Lac) proton, which was correlated with the γ–CH$_3$ proton. HMBC correlations (see Table 1 and Fig. 2) further supported the structure of each unit. According to the foregoing NMR correlations and the NMR data comparison of

![Fig. 1. Structures of compounds 1–3, 2a, 2b, and 2c.](image-url)
The data with the same labels in each column may be interchanged.

Table 1

| δ_C (125 MHz) and 1H (500 MHz) NMR spectroscopic data of streptodepsipeptide P11A (2). | δ_C, type | δ_H (J in Hz) | HMBC (H to C) | δ_H (J in Hz) | HMBC (H to C) |
|---|---|---|---|---|---|
| C-O | Val | 28.77, CH | 2.35, m | C_1, C_2, C_3, C_4, C_5 |
| L-Lac | 172.65, C | | | | |
| L-Lac | 172.80, C | | | | |
| L-Lac | 172.55, C | | | | |
| L-Val | 172.22, C | | | | |
| L-Val | 172.06, C | | | | |
| L-Val | 171.50, C | | | | |
| D-Hiv | 170.86, C | | | | |
| D-Hiv | 171.16, C | | | | |
| L-Val | 171.40, C | | | | |
| D-Val | 170.28, C | | | | |
| D-Val | 170.42, C | | | | |
| L-Lac | 170.39, C | | | | |
| α-CH - O | D-Hiv | 78.93, CH | 4.99, d (3.2) | C_1, C_2, C_3, C_4, C_5, L-Val-C_1 |
| D-Hiv | 78.69, CH | 5.02, d (3.2) | C_1, C_2, C_3, C_4, C_5, L-Val-C_1 |
| D-Hba | 75.56, CH | 5.11, d (6.6, 4.3) | C_1, C_2, C_3, C_4, C_5, L-Val-C_1 |
| L-Lac | 70.41', CH | 5.33, q (6.8) | C_1, C_2, C-Val-C_1 |
| L-Lac | 70.51', CH | 5.27, q (6.8) | C_1, C_2, C-Val-C_1 |
| L-Lac | 70.53', CH | 5.33, q (6.8) | C_1, C_2, C-Val-C_1 |
| α-CH - N | L-Val | 60.75, CH | 3.96, d (10.0, 5.8) | C_1, C_2, C_3, C_4, C_5, L-Val-C_1 |
| L-Val | 60.68, CH | 3.97, d (10.0, 6.0) | C_1, C_2, C_3, C_4, C_5, L-Val-C_1 |
| L-Val | 60.11, CH | 4.01, d (10.0, 6.2) | C_1, C_2, C_3, C_4, C_5, L-Val-C_1 |
| D-Val | 58.98, CH | 4.13, d (9.8, 8.0) | C_1, C_2, C_3, C_4, C_5, D-Hiv-C_1 |
| D-Val | 59.25, CH | 4.08, d (9.2, 8.0) | C_1, C_2, C_3, C_4, C_5, D-Hiv-C_1 |
| D-Val | 59.25, CH | 4.08, d (9.2, 7.9) | C_1, C_2, C_3, C_4, C_5, D-Hiv-C_1 |

The data with the same labels in each column may be interchanged.
biosynthetic pathway, suggesting that the 12 identified compounds were isolated from strain P11-23B and might have the same overall structure. The NMR data are listed in Table 1. The molecular formula of C34H59N4O11 was determined to be C34H59N4O11, with a m/z of 870.5064 (calcd for C34H59N4O11, 870.5070). The 1H and 13C NMR spectrum showed 52 carbon signals for 12 carbonyls (δC 125 MHz) and 20 methyls (δC 125 MHz), indicating the presence of a 12-unit depsipeptide, named as streptodepsipeptide P11A. Its 13C and 1H NMR spectroscopic data of streptodepsipeptide P11A (Table 2) was further investigated for its structure by chiral HPLC and GC. Further detailed NMR spectroscopic analysis, in combination with the HREMS data, indicated that the structure of the 12-unit compound was similar to that of the D-Hiv moiety in streptodepsipeptide P11A. The 13C and 1H NMR data (Table 2) of the 12 isolated cyclodepsipeptides (0.8 μM) also had a stronger antiproliferative effect than DOX (0.8 μM) and 10 μM streptodepsipeptide P11A (0.8 μM) caused an increase of 20.40% in total apoptotic cells (early and late apoptotic cells), when compared to the control (CON, Fig. 5).

Streptodepsipeptide P11A (2) was further investigated for its effects on several important tumor metabolic regulators including HK2 (glycolysis), PFKFB3 (glycolysis), PKM2 (glycolysis), GLS (glutaminolysis), and FASN (lipogenesis). Firstly, the expression levels

| Table 2 | 13C (125 MHz) and 1H (500 MHz) NMR spectroscopic data of streptodepsipeptide P11B (3, in CDCl3). |
|----------|---------------------------------------------------------------------------------------------|
| δC (125 MHz) | δH (J in Hz) | δC (125 MHz) | δH (J in Hz) | δC (125 MHz) | δH (J in Hz) |
| C=O | 59.62, CH | 4.05, dd (10.0, 7.6) | 19.58, CH | 0.95–1.10 |
| 172.98, C | 59.33, CH | 4.07, dd (10.0, 8.2) | 19.53, CH | 0.95–1.10 |
| 172.52, C | 58.75, CH | 4.16, dd (9.8, 8.2) | 19.50, CH | 0.95–1.10 |
| 172.44, C | β-CH | 17.73, CH | 1.44–1.49 | 19.44, CH | 0.95–1.10 |
| 172.34, C | L-Lac | 17.69, CH | 1.44–1.49 | 19.40, CH | 0.95–1.10 |
| 172.28, C | 17.54, CH | 1.44–1.49 | 19.33, CH | 0.95–1.10 |
| 172.07, C | 17.11, CH | 1.44–1.49 | 19.22, CH | 0.95–1.10 |
| 171.49, C | β-CH | 16.91, CH | 0.98 | 16.78, CH | 0.98 |
| 170.85, C | D-Hiv | 30.43, CH | 2.36, m | 16.91, CH | 0.98 |
| 170.72, C | D-Hiv | 30.43, CH | 2.36, m | 16.78, CH | 0.98 |
| 170.64, C | Val | 28.92, CH | 2.17–2.40 | L-Val | 7.74, d (5.9) |
| 170.49, C | 28.71, CH | 2.17–2.40 | L-Val | 7.74, d (6.3) |
| 170.20, C | 28.68, CH | 2.17–2.40 | L-Val | 7.79, d (6.0) |
| 69.21, CH | 4.94, d (3.2) | 28.68, CH | 2.17–2.40 | L-Val | 7.79, d (8.2) |
| 78.57, CH | 5.04, d (3.0) | 28.59, CH | 2.17–2.40 | L-Val | 8.00, d (7.6) |
| 71.20, CH | 5.22, q (7.0) | 28.46, CH | 2.17–2.40 | L-Val | 7.79, d (8.2) |
| 71.00, CH | 5.20, q (7.0) | 28.46, CH | 2.17–2.40 | L-Val | 8.00, d (7.6) |
| 70.75, CH | 5.32, q (7.0) | 28.46, CH | 2.17–2.40 | L-Val | 8.00, d (7.6) |
| 70.33, CH | 5.31, q (7.0) | 28.46, CH | 2.17–2.40 | L-Val | 8.00, d (7.6) |
| 60.97, CH | 3.91, dd (10.0, 5.9) | 19.76, CH | 0.95–1.10 |
| 60.71, CH | 3.96, dd (10.0, 6.3) | 19.76, CH | 0.95–1.10 |
| 59.78, CH | 4.01, dd (9.8, 6.0) | 19.63, CH | 0.95–1.10 |
of HK2, PFKFB3, PKM2, GLS, and FASN in four different glioma cell lines of SHG-44, U87-MG, U251, and C6 were tested by western blot. It has been found that all five tumor metabolic regulators were highly expressed in the U87-MG cells (Fig. 6A). Thus, the effects of streptodepsipeptide P11A (2) on expression levels of these regulators in the U87-MG cells were evaluated. U87-MG cells were treated by streptodepsipeptide P11A (2) (5 μM or 10 μM) for 48 h. Protein prepared from the streptodepsipeptide P11A-treated U87-MG cells was subjected to western blot analysis. The results (Fig. 6B) indicated that HK2, PFKFB3, GLS, and FASN were highly down-regulated in the streptodepsipeptide P11A-treated U87-MG cells, when compared to negative control (CON, U87-MG cells treated with streptodepsipeptides P11B (3) or DOX as drug positive control or without compound as negative control for 72 h at different concentrations. Values are means ± S.D. from five independent experiments.

**Table 3**

Activity of streptodepsipeptides P11A (2) and P11B (3) inhibiting proliferation of glioma cells (IC50: μM).

| Compounds   | Glioma Cells (GC) | human astrocytes (HA) |
|-------------|-------------------|-----------------------|
|             | U251              | U87-MG                | SHG-44 | C6   |
| Valinomycin (1) | 7.6 ± 0.7*a      | 30.0 ± 2.8*a          | 21.0 ± 2.9*a | 24.0 ± 2.0*a | NT       |
| P11A (2)    | 0.4 ± 0.0         | 0.4 ± 0.0             | 0.3 ± 0.0 | 0.3 ± 0.0 | 9.1 ± 0.2 |
| Ratios of IC50HA/IC50GC | 23 23 30 30      | 23 23 30 30           |        |
| P11B (3)    | 0.5 ± 0.0         | 0.2 ± 0.0             | 1.4 ± 0.2 | 0.1 ± 0.0 | 3.5 ± 0.5 |
| Ratios of IC50HA/IC50GC | 7 18 3 35        | 7 18 3 35             |        |
| Doxorubicin  (DOX) | 3.3 ± 0.7       | 0.4 ± 0.0             | 1.9 ± 0.0 | 0.5 ± 0.1 | 8.7 ± 1.2 |
| Ratios of IC50HA/IC50GC | 3 22 5 17        | 3 22 5 17             |        |

*a The unit of the IC50 values is nM, NT: No testing.

Fig. 3. Streptodepsipeptides P11A (2) and P11B (3) inhibited the proliferation of glioma cells. Glioma cells were treated with streptodepsipeptides P11A (2) and P11B (3) or DOX as drug positive control or without compound as negative control for 72 h at different concentrations. Values are means ± S.D. from five independent experiments.

Fig. 4. Streptodepsipeptide P11A (2) arrested cell cycle in U87-MG and U251 cells. U87-MG and U251 cells were incubated with streptodepsipeptide P11A (2) (0.8 μM), DOX (0.8 μM) as positive control, or without compound treatment as negative control (CON) for 12 h and then stained with PI and subjected to flow cytometric analysis for cell distribution at each phase of cell cycle. Percentage of cells at each stage of the cell cycle was shown. The proportion of cells in the G0/G1 phase of the cell cycle was greatly enhanced.
without streptodepsipeptide P11A treatment), while PKM2 was slightly down-regulated. Similar results were also obtained for the known valinomycin (1). As shown in Fig. S83, valinomycin (1) remarkably reduced expression levels of HK2, FANS, GLS, and had little effect on the downregulation of PKM2. In order to determine if streptodepsipeptide P11A (2) selectively affected the expressions of these tumor metabolic enzymes, its effects on regulation of aconitase 2 (ACO2), ATP synthase beta (ATPB), and cytochrome C (Cyto-C) were also investigated [ACO2, ATPB, and Cyto-C are important regulators in the processes of tricarboxylic acid cycle and oxidative phosphorylation, which are the predominant metabolic processes of glucose in the normal cells (Galluzzi et al., 2013; Jones and Schulze, 2012)]. As presented in Fig. 6C, streptodepsipeptide P11A (2) had no obvious effects on ACO2 and ATPB expression levels, but increased the level of Cyto-C. These data suggested that streptodepsipeptide P11A (2) might selectively regulate tumor metabolic regulators of HK2, PFKFB3, PKM2, GLS, and FASN. The increased expression level of Cyto-C also implied that streptodepsipeptide P11A (2) might change the tumor metabolic pathway to the process of oxidative phosphorylation.

Valinomycin (1) is known to induce uptake of potassium in membrane of erythrocyte (Bhattacharyya et al., 1971). Therefore, the ability of streptodepsipeptide P11A (2) to enhance the K⁺ permeability of human erythrocytes was also evaluated. Human erythrocytes were treated with tested compound (2) or positive control valinomycin (1) for 90 min. The results (Table 5) showed that streptodepsipeptide P11A (2) at concentrations of 0.01 μM, 0.05 μM, and 0.1 μM induced 23.36%, 66.46%, and 86.10% increase of intracellular K⁺ in erythrocytes, respectively, when compared to the negative control (CON, human erythrocyte without compound treatment). The positive control valinomycin (1) at the same concentrations also enhanced the K⁺ uptake by 19.06%, 83.43%, and 75.3%, respectively. These data indicated that both valinomycin (1) and streptodepsipeptide P11A (2) had the property to significantly induce uptake of K⁺ in membrane of erythrocyte.

Some small molecular compounds have been reported to have antitumor activity by targeting tumor metabolic regulators, such as hexokinase (HK) inhibitors: 2-deoxyglucose, lonidamine, and 3-bromopyruvate; PKM2 inhibitor: shikonin and TLN 232; FANS inhibitors: orlistat, cerulenin, and EGCG (Galluzzi et al., 2013; Jones and Schulze, 2012; Menendez and Lupu, 2007). It was noted that most of these active antitumor agents targeted only one tumor metabolic regulator. Interestingly, streptodepsipeptide P11A (2) had obvious effects on several important tumor metabolic regulators, which were from different metabolic pathways.

Table 4
Analysis of cell cycle in streptodepsipeptide P11A-treated U87-MG and U251 cells.

| Treatment (12 h) | G0/G1 (%) | S (%) | G2/M (%) | Compound (G0/G1) – CON (G0/G1) |
|-----------------|-----------|-------|-----------|-----------------------------|
| U87-MG          |           |       |           |                             |
| Control (CON)   | 40.96     | 38.56 | 20.48     |                             |
| DOX (0.8 μM)    | 90.65     | 5.52  | 3.83      | 49.69%                      |
| P11A (2, 0.8 μM)| 81.88     | 9.12  | 9.00      | 40.92%                      |
| U251            |           |       |           |                             |
| Control (CON)   | 44.48     | 36.81 | 18.71     |                             |
| DOX (0.8 μM)    | 71.45     | 15.51 | 13.04     | 26.97%                      |
| P11A (2, 0.8 μM)| 62.39     | 21.92 | 15.69     | 17.91%                      |

* Control (CON): U87-MG and U251 cells were treated without compounds.

![Fig. 5. Streptodepsipeptide P11A (2) induced apoptosis in U87-MG cells. U87-MG cells were treated with streptodepsipeptide P11A (2) (0.8 μM), DOX (10.0 μM) as positive control, or without compound treatment as negative control (CON) for 72 h, stained with annexin-V FITC and PI, and then analyzed by flow cytometry. (B1: necrotic cells; B2: late apoptotic cells; B3: normal glioma cells; B4: early apoptotic cells).](image)

![Fig. 6. A: Expression levels of HK2, PFKFB3, PKM2, GLS, and FASN in different glioma cell lines. B: Streptodepsipeptide P11A (2) reduced expression levels of HK2, PFKFB3, PKM2, GLS, and FASN in U87-MG cells. C: Effect of streptodepsipeptide P11A (2) on expression levels of ATPB, ACO2, and Cyto-C in U87-MG cells. U87-MG cells were treated with streptodepsipeptide P11A (2) (5 and 10 μM) or without streptodepsipeptide P11A (2) as negative control (CON) for 48 h. Protein extracted from cells was subjected to western blot analysis (HK2: hexokinase 2; PFKFB3: 6-phosphofructo-2-kinase/2, 6-bisphosphatase 3; PKM2: pyruvate kinase M2; GLS: glutaminase; FASN: fatty acid synthase; β-actin: internal control).](image)
proposed that modulating multiple targets could be beneficial for prevention and treatment of complex human diseases such as cancer (Bishayee and Block, 2015; Morphy and Rankovic, 2007). Whether streptodepsipeptide P11A (2) has the potential for developing novel anticancer drug need to be further evaluated.

3. Concluding remarks

An actinomycete Streptomyces sp. P11-23B that produced anti-proliferative cyclodepsipeptides was isolated from a sample of marine mud. Chemical investigation of a crude extract prepared from the cultures of this isolated strain P11-23B resulted in the isolation and identification of two new cyclodepsipeptides, named as streptodepsipeptides P11A (2) and P11B (3). It was found that both new cyclodepsipeptides significantly suppressed proliferation of four different glioma cell lines. Further investigation demonstrated that streptodepsipeptide P11A (2) induced apoptosis in glioma cells, arrested cell cycle at the G0/G1 phase, and down-regulated expression levels of HK2, PFKFB3, PKM2, GLS, and FASN, the important tumor metabolic regulators of glycolysis, glutaminolysis, and lipogenesis. These results indicated that regulating multiple glioma metabolic enzymes might be one of the antitumor mechanisms of streptodepsipeptide P11A (2). To the best of our knowledge, this is the first report of such a possible mechanism for this class of streptodepsipeptides. However, how streptodepsipeptide P11A (2) regulates these metabolic regulators, and what the anti-glioma activity is of this new bioactive cyclodepsipeptide in animal models, need to be further investigated.

4. Experimental section

4.1. General experimental procedures

Melting points were measured with a WXR-4 microscope apparatus and are uncorrected. Optical rotations were measured on a JASCO DIP-370 digital polarimeter. IR spectra were recorded on an AVATAR 370 FT-IR spectrometer (Thermo Nicolet). AA800 atomic absorption spectrometry (PerkinElmer Co., LTD.) was used to determine K⁺ concentration. NMR spectra were acquired on a Bruker 500 spectrometer using standard pulse programs and acquisition parameters. Chemical shifts were expressed in δ (ppm) and referred to the NMR solvent CDC3H2. RESIMS data were acquired on an Agilent 6230 TOF LC/MS spectrometer. MS-MS data were obtained from AB Triple TOF 5600plus System (AB SCIEX, Framingham, USA) in the optimal MS conditions: scan range m/z 100–1500, positive ion mode, source voltage = 5.5 kV, source temperature 600 °C, gas pressure 50 psi, curtain gas (N2) 30 psi, maximum error ≤ 5 ppm, collision energy 50 V with a collision energy spread ± 20 V. The separation of pure compounds was conducted on an Agilent 1260 HPLC system with DAD detector. A chirex 3126 (D)-penicillamine column (150 × 4.6 mm, Phenomenex, Shanghai, China) was used for the chiral HPLC analysis. GC analysis was conducted on an Agilent 6890N gas chromatograph system using a DB-624 capillary column (30 m × 0.53 mm, 3.0 µm, Agilent Technologies). N2 (4.0 mL/min) was used as carrier gas and FID as a detector. The detector and injection port temperatures were set at 250 °C and 200 °C, respectively. The column temperature was 100 °C in 2 min, raised with 10 °C/min to 200 °C, and then kept at 200 °C for 5 min. Octadecyl-functionalized silica gel (ODS, Cosmosil 75C18 Prep, Nacalai Tesque Inc., Kyoto, Japan) was used for column chromatography (CC). HPLC and analytic grade solvents were purchased from the Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). Doxorubicin (DOX, >98.0%), D-valine (D-Val), L-valine (L-Val), L-lactate (L-Lac), D-α-hydroxyisovaleric acid (D-Hiv), and D-2-hydroxybutyric acid (D-Hba) were purchased from Sigma. Human glioma U251, U87-MG, and SHG-44 cells, and rat glioma C6 cells were purchased from the Cell Bank of the Chinese Academy of Sciences. Normal human astrocytes (HA, Cat. No. 1800) were obtained from ScienCell. Gause’s-agar was purchased from Guangdong Huankai Microbial Science and Technology Co. Ltd. (Guanzhou, China).

4.2. Isolation and identification of marine Streptomyces sp. P11-23B

The strain P11-23B was isolated from a mud sample of marine tidal flat, which was collected from the coast of the East China Sea, close to Zoushan City, China, in August 2013. The marine mud sample (1.0 g) were dried at 28 °C for 5 days in a sterile culture dish. The dried sample was diluted to 1 × 10⁻⁴ g/ml with sterile natural sea water, and then shaken on a rotary shaker at 180 rpm at 28 °C for 10 min. A suspension sample (200 μL) was coated across plates with Gause’s-agar medium and then incubated at 28 °C for 7 days. The single colony (strain P11-23B) that grew well was transferred onto Gause’s-agar media. Working stocks were prepared on Gause’s-agar slants and stored at 4 °C for further use.

The taxonomic identity of isolate strain P11-23B was determined by 16S rDNA sequence analysis, which was conducted by Majorbio (Shanghai, China). The DNA sequence using BLAST (nucleotide sequence comparison) was compared to the GenBank database. The 16S rDNA sequence of strain P11-23B has been deposited in GenBank (accession number: KT9331361). Voucher strains of Streptomyces sp. P11-23B (No. P1123B) are preserved at the Laboratory of Institute of Marine Biology, Ocean College, Zhejiang University, China.

4.3. Fermentation of strain P11-23B

A homogenized colony of isolate P11-23B was transferred into a 500 mL Erlenmeyer flask containing 200 mL of Gause’s liquid medium that was incubated for 7 days at 28 °C on a rotary shaker (180 rpm) to produce seed broth. The seed broth (5 mL) was then inoculated into a 500 mL Erlenmeyer flask, which contained 200 mL of Gause’s liquid medium. The flasks were incubated at 28 °C on a rotary shaker at 180 rpm for 14 days. A total of 50.0 L fermentation broth was made for this study.

4.4. Isolation of streptodepsipeptides and valinomycin

The fermentation broth of isolated strain P11-23B (50.0 L) was filtered to harvest pellets and fermentation solution. The pellets
were extracted by percolation at room temperature with MeOH three times (2.0 L, 4 h, each) to give a MeOH extract (Part A). The fermentation solution was applied to a column of Diaion HP-20 eluting with H2O (5.0 L) and then MeOH (5.0 L) to afford MeOH eluent (Part B). Part A and Part B were combined and then concentrated in vacuo to yield a crude extract (7.56 g), which was fractionated by ODS CC (800 × 30 mm) eluting in turn with MeOH: H2O (70:30 and 100:0, v/v) to give two fractions 70M and 100M. Fraction 100M was further fractionated by ODS CC (600 × 30 mm) eluting with MeOH: H2O (90:10, v/v) to yield 40 fractions (each 20 mL). Fractions 21–30, containing cyclodepsipeptides, were combined and then dried in vacuo to furnish crude cyclodepsipeptides. These mixtures were finally separated by HPLC (Zorbax SB-C18 column: 250 × 9.4 mm, 5 μm; mobile phase: MeOH; flow rate: 1.0 mL/min; detection wavelength: 210 nm) to give valinomycin (1, 36.8 mg, tR 20.1 min), streptodepsipeptide P11A (2, 17.6 mg, tR 18.3 min) and streptodepsipeptide P11B (3, 6.8 mg, tR 17.1 min).

Valinomycin (1): Colorless amorphous powder; molecular formula C52H86N6O18; tR 17.1 min (MeOH); [M + Na]+ 1128.6647 (calcd for C52H85N6O18, 1128.6655).

Streptodepsipeptide P11A (2): Colorless amorphous powder; molecular formula C54H94N7O18, 1128.6655. For 13C and 1H NMR spectroscopic data, see Table S2; HRESIMS m/z [M+Na]+ 1128.6647 (calcd for C54H94N7O18, 1128.6655).

Streptodepsipeptide P11B (3): Colorless amorphous powder; molecular formula C52H85N6O18; tR 17.1 min (MeOH); [M + Na]+ 1128.6697 (calcd for C52H85N6O18, 1128.6697).

4.5. Alkaline hydrolysis of streptodepsipeptide P11A (2)

Streptodepsipeptide P11A (2, 5.0 mg) was hydrolyzed using 3N LiOH (1 mL) in MeOH: H2O (3:1, v/v) with gentle shaking at room temperature for 12 h. The reaction mixture was neutralized with 3N HCl to pH 6–8 and then dried under reduced pressure to give a residue. Hydrolytic products of 2a (1.7 mg, tR 13.1 min), 2b (1.3 mg, tR 20.0 min), and 2c (0.3 mg, tR 16.1 min) were next purified from this residue by HPLC using a Zorbax SB-C18 column (150 × 4.6 mm, 5 μm) at conditions of flow rate of 1.0 mL/min, detection wavelength of 210 nm, and a gradient mobile phase. MeOH and water were employed as mobile phase A and phase B, respectively. This binary gradient program was 0.0–20.0 min with 10–60% phase A, 20.1–25.0 min with 100% phase A, and 25.1–30.0 with 10% phase A.

D-Hva-D-Val (2c): Colorless amorphous powder; molecular formula C46H76NO14; HRESIMS m/z [M–H]– 202.1087 (calcd for C46H75NO14, 202.1079), [M+H]+ 204.1230 (calcd for C46H75NO14, 204.1236), [M+Na]+ 226.1053 (calcd for C46H77NaO14, 226.1055).

4.6. Acid hydrolysis of valinomycin (1), streptodepsipeptides P11A (2) and P11B (3), L-Lac-L-Val (2a), D-Hiv-D-Val (2b), and D-Hba-D-Val (2c)

Valinomycin (1), streptodepsipeptides P11A (2) and P11B (3) (2.0 mg, each) were individually dissolved in 6N HCl (1.0 mL) and heated at 110 °C in an evacuated glass ampoule for 24 h. After cooling, each hydrolysate was dried under N2 and then under vacuum to give the corresponding residues. Half of each residue was dissolved in H2O (0.2 mL) to produce sample A for chiral HPLC analysis. The remaining residue was dissolved in MeOH (0.2 mL) to give sample B for GC analysis. In the same way, L-Lac-L-Val (2a, 0.5 mg), D-Hiv-D-Val (2b, 0.5 mg), and D-Hba-D-Val (2c, 0.2 mg) were individually hydrolyzed to give samples C, D, and E, respectively, for chiral HPLC analysis.

4.7. Configuration assignment of each unit in the valinomycin (1), streptodepsipeptides P11A (2) and P11B (3), L-Lac-L-Val (2a), D-Hiv-D-Val (2b), and D-Hba-D-Val (2c)

Each of the samples A, C, D, and E prepared above and the authentic D-Val and L-Val were analyzed using a Chirex 3126 (D-penicillamine column (150 × 4.6 mm, Phenomenex) with detection at 254 nm and temperature at 22 °C. Aqueous CuSO4 (1 mM) was used as mobile phase. The free amino acids in the acid hydrolysates of valinomycin (1) and streptodepsipeptides P11A (2) and P11B (3) were found to be L-valine (tR, 23.7 min) and D-valine (tR, 37.1 min) by comparison with retention times of authentic amino acids. The acidic products of L-Lac-L-Val (2a), D-Hiv-D-Val (2b), and D-Hba-D-Val (2c) were found to be L-Val for 2a and D-Val for 2b and 2c. The sample B prepared from each compound was analyzed by GC. GC analyses showed that valinomycin (1) and streptodepsipeptide P11B (3) produced L-Val and D-Hiv and streptodepsipeptide P11A (2) produced L-Hba, D-Hiv, and as compared with authentic L-Lac (tR 7.32 min), D-Hba (tR 8.54 min), and D-Val (tR 9.35 min).

4.8. Biological assays

Sulforhodamine B (SRB) assay. The previously described sulforhodamine B (SRB) assay (Chen et al., 2015; Yu et al., 2014, 2015) was applied to evaluate the activity of the isolated streptodepsipeptides inhibiting the proliferation of glioma U87-MG, U251, SHG-44, and C6 cells. Doxorubicin (DOX) was used as the positive control (CON).

 Annexin V-FITC/PI double staining assay. The quantification of apoptotic cells induced by streptodepsipeptide P11A (2) was made by annexin V-FITC/PI double staining using an annexin V apoptosis detection kit (Chen et al., 2015; Yu et al., 2014, 2015). Glioma cells were treated with the tested compound for 72 h and flow cytometry was used to determine fluorescence using emission wavelength at 530 nm and 575 nm and excitation wavelength at 488 nm.

Cell cycle assay. Cell cycle perturbation induced by streptodepsipeptide P11A (2) was analyzed by propidium iodide (PI) DNA staining using flow cytometry. The detailed protocol is described in Xin et al., 2012.

Western blot analysis. Western blot was used to determine the expression levels of metabolic regulators. The detailed procedure including protein sample preparation, determination of protein concentration, and western blot analysis was carried out as for Yu et al., 2015.
Determination of intracellular K⁺ concentration (Bhattacharyya et al., 1971; Li and Yang, 2009; Lu et al., 2006). Briefly, fresh healthy human blood was centrifuged at 660 g for 10 min at 4 °C. The precipitated erythrocytes were washed with GNS (glucose and normal saline injection) buffer (50 g/L glucose and 9 g/L NaCl) and then centrifuged at 660 g for 5 min in three repeated operations. Washed erythrocytes were suspended with GNS buffer (1: 1) to make a 50% erythrocyte suspension. The prepared erythrocyte suspension (1 mL) was treated with different concentrations of tested compounds in the KCl isosotonic solution (3 mL) for 90 min at 37 °C. After terminating the treatment by using an ice bath for 1 min, the treated suspension was centrifuged at 660 g for 10 min. The treated erythrocytes were washed with cold GNS (3 mL) five times to remove extracellular K⁺, and then haemolyzed by ultrapure H₂O at 4 °C for overnight. Haemolyzed solutions were centrifuged at 10,700 g for 30 min at 4 °C to give cytoplasm and cell membranes. The cell membranes were washed by ultrapure H₂O twice (each 5 mL) to give a wash solution, which was centri-

Precipitated erythrocytes were washed with GNS (glucose and normal saline injection) buffer (50 g/L glucose and 9 g/L NaCl) and then haemolyzed by ultrapure H₂O at 4 °C for overnight. Haemolyzed solutions were centrifuged at 10,700 g for 30 min at 4 °C to give cytoplasm and cell membranes. The cell membranes were washed by ultrapure H₂O twice (each 5 mL) to give a wash solution, which was centri-

The prepared erythrocyte suspension (1 mL) was treated with different concentrations of tested compounds in the KCl isosotonic solution (3 mL) for 90 min at 37 °C. After terminating the treatment by using an ice bath for 1 min, the treated suspension was centrifuged at 660 g for 10 min. The treated erythrocytes were washed with cold GNS (3 mL) five times to remove extracellular K⁺, and then haemolyzed by ultrapure H₂O at 4 °C for overnight. Haemolyzed solutions were centrifuged at 10,700 g for 30 min at 4 °C to give cytoplasm and cell membranes. The cell membranes were washed by ultrapure H₂O twice (each 5 mL) to give a wash solution, which was centri-

Acknowledgments
This study was supported by a grant from the National Natural Science Foundation of China (No. 81273428). We appreciate Mrs. Yaer Zhu (the Analysis Center for Agrobiology and Environmental Sciences of Zhejiang University) for performing the NMR spectroscopy, Dr. Zhiwei Ge and Mrs. Yaer Zhu (the Analysis Center for Agrobiology and Environmental Sciences of Zhejiang University) for MS-MS and GC analyses.

Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.phytochem.2016.12.010.

References
Bhattacharyya, P., Epstein, W., Silver, S., 1971. Valinomycin-induced uptake of po-
tassium in membrane vesicles from Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 68, 1488–1492.

Bishayee, A., Block, K., 2015. A broad-spectrum integrative design for cancer pre-
vention and therapy: the challenge ahead. Semin. Cancer Biol. 35, 1–10.

Bhattacharyya, P., Epstein, W., Silver, S., 1971. Valinomycin-induced uptake of po-
tassium in membrane vesicles from Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 68, 1488–1492.

Bhattacharyya, P., Epstein, W., Silver, S., 1971. Valinomycin-induced uptake of po-
tassium in membrane vesicles from Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 68, 1488–1492.

Bhattacharyya, P., Epstein, W., Silver, S., 1971. Valinomycin-induced uptake of po-
tassium in membrane vesicles from Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 68, 1488–1492.